SCHOLAR ROCK
Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular ... level. They believe this approach, acting in the disease microenvironment, avoids the historical challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path. The company is advancing its lead product candidate, SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, into clinical development for the treatment of spinal muscular atrophy, or SMA. They expect to initiate a Phase 1 clinical trial in the second quarter of 2018. Utilizing its proprietary platform, they are also creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including other neuromuscular disorders, cancer, fibrosis, and anemia.
SCHOLAR ROCK
Industry:
Biopharma Biotechnology Medical Therapeutics
Founded:
2012-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.scholarrock.com
Total Employee:
101+
Status:
Active
Contact:
857-259-3860
Email Addresses:
[email protected]
Total Funding:
358 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
AcertaPharma
Acerta Pharma provides drug discovery and development services for oncology and autoimmune diseases.
Akston Biosciences
Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics.
Aktis Oncology
Aktis Oncology is a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals.
Aligos Therapeutics
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Ambys Medicines
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.
AmpliPhi Biosciences
AmpliPhi Biosciences is focused on developing novel bacteriophage-based therapeutics.
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Axol Bioscience
Axol Bioscience sells live human cell cultures and provides services such as genome editing to researchers.
BackBeat Medical
BackBeat Medical Inc. is a medical technology company founded in 2010 to develop novel cardiac stimulation-based therapies.
Biowave
Smarter neurotechnology medical devices that provide instant, long lasting pain relief.
Chroma Medicine
Chroma Medicine is a new genomic medicine company working on epigenetic editing.
Decibel Therapeutics
Decibel Therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair, and restore hearing.
Dermata Therapeutics
Dermata is a biotechnology company that focuses on making major advancements in the treatment of serious diseases treated by dermatologists.
Divide and Conquer
Divide & Conquer is a biotechnology company focused on discovery and development of a new class of oncology therapeutics
Emerald Cloud Lab
Emerald Cloud Lab is building technology platforms to drive the future of biotechnology innovation.
Gadeta
Gadeta is a research and development company that develops immunotherapies for cancer.
Gallant Pet
Gallant Pet is a pet service company that develops a stem cell therapy intended for dog wounds.
Genocea Biosciences
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies.
GID BIO
GID BIO is a global leader in cellular therapy, offering a tissue processing platform.
GigaGen
GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.
GLyPharma Therapeutic
GLyPharma Therapeutic Inc. develops oncology drugs.
Glyscend
Glyscend develops a revolutionary approach to treating type 2 diabetes.
Goodwin Biotechnology, Inc.
Goodwin Biotechnology is a biotechnology company that offers biologics process development and purification bioconjugation services.
Grove Biopharma
Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges.
Immunic Therapeutics
Immunic is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies.
Precigen
Precigen is a life sciences company researching and developing bio-therapeutic control systems to minimize toxicity.
Janpix
Janpix operates as an oncology-focused startup.
Laronde
Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.
Luminopia
Luminopia is pioneering a new class of treatments for significant neuro-visual disorders.
Mitobridge
Mitobridge is discovering and developing small molecule therapeutics that improve mitochondrial functions.
Mosaic Biosciences
Mosaic Biosciences is a developer of synthetic extracellular materials used to support natural tissue regeneration.
MSI Methylation Sciences
MSI Methylation Sciences is a biotechnology company that develops and markets S-Adenosyl Methionine.
NeuroNascent
Neuronascent discovers and develops small molecule therapeutics for depression and neurodegenerative diseases.
NFlection Therapeutics
NFlection focuses on the development of novel therapies to address the needs of patients.
Nimbus Apollo
Nimbus Apollo, Inc. research and develops drugs that treats non-alcoholic steatohepatitis.
NuMedii
NuMedii is a biotechnology company that discovers and de-risks effective drugs by translating life sciences big data into therapies.
Oncorus
Oncorus is an immuno-oncology company developing oncolytic viruses to fight cancer.
OncoStem Diagnostics
OncoStem is a diagnostic oncology company focused on discovering and developing novel tests for improved treatment planning.
Organovo Holdings
Organovo develops a range of tissue and disease models for medical research and therapeutic applications.
Perlara
Perlara, PBC is precision drug discovery that leaves no mutation behind.
Regenacy Pharmaceuticals
Regenacy Pharmaceuticals Provides Healthcare Services.
Revitope Oncology
Revitope is developing a novel approach to cancer immunotherapy.
Ceptur Therapeutics
Revolutionizing gene silencing by developing targeted oligonucleotide therapeutics based on U1 Adaptor technology
Solstice Biologics
Solstice Biologics is a biotech company that provides solutions for targeting and delivering nucleic acid therapeutics.
SynerFuse
SynerFuse is a provider of traditional spine implants intended to offer long-term pain management without the use of addictive opioids
Vaxess Technologies
Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies.
Xcell Biosciences
Xcell Biosciences is a next-generation development and manufacturing platform for enhanced cell therapy performance.
ZZ Biotech
A clinical stage company developing innovative biologic treatments for ischemic stroke.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Polaris Partners
Polaris Partners investment in Post-IPO Equity - Scholar Rock
Invus
Invus investment in Post-IPO Equity - Scholar Rock
Redmile Group
Redmile Group investment in Post-IPO Equity - Scholar Rock
Samsara BioCapital
Samsara BioCapital investment in Post-IPO Equity - Scholar Rock
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Scholar Rock
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Post-IPO Debt - Scholar Rock
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Scholar Rock
Invus
Invus investment in Series C - Scholar Rock
Redmile Group
Redmile Group investment in Series C - Scholar Rock
EcoR1 Capital
EcoR1 Capital investment in Series C - Scholar Rock
Official Site Inspections
http://www.scholarrock.com Semrush global rank: 761.78 K Semrush visits lastest month: 52.48 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Scholar Rock"
Learn About Our Values and Team - Scholar Rock
We believe exploration is the forerunner of transformation. Our team members work with passion and uphold our values. Meet our team.See details»
Scholar Rock Board of Directors
Our board of directors consists of leaders from current and former biopharmaceutical companies as well as other highly esteemed institutions.See details»
Scholar Rock - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 857-259-3860 Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling …See details»
Investor Information - Scholar Rock, Inc.
Nov 4, 2024 Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. News View More Press Releases. November 15, 2024 Scholar Rock Reports New Employee Inducement Grants …See details»
Press Release - Scholar Rock, Inc.
Apr 10, 2023 [email protected] 212-583-2729 Source: Scholar Rock. Return to Press Releases Page. See our Events & Presentations. RSS Feeds; Search; Footer. SCHOLAR …See details»
Scholar Rock - LinkedIn
Scholar Rock | 8,794 followers on LinkedIn. Scholar Rock is a biopharmaceutical company that discovers, develops and delivers life-changing therapies | Scholar Rock is a biopharmaceutical company ...See details»
Scholar Rock Announces Leadership Change
Aug 3, 2021 [email protected]. Media Ariane Lovell Finn Partners [email protected] 917-565-2204 Source: Scholar Rock. Return to Press …See details»
Scholar Rock Provides Corporate Update and Highlights Priorities …
CAMBRIDGE, Mass., January 04, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular …See details»
Scholar Rock - Senior Director, Market Insights
Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. Summary of Position: This Senior Director, Market Insights role is an exciting opportunity to be an integral part of the …See details»
Scholar Rock Provides Corporate Update and Highlights Priorities …
Jan 4, 2024 Investors & Media Rushmie Nofsinger Scholar Rock [email protected] [email protected] 857-259-5573 Contacts Investors & Media Rushmie Nofsinger Scholar …See details»
Scholar Rock Announces FDA Clearance of IND Application to …
CAMBRIDGE, Mass., January 23, 2024--Scholar Rock (NASDAQ: SRRK) (the Company), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal …See details»
Learn About Our Unique Platform Here at Scholar Rock
A Look to the Future. We use our platform to inspire newfound hope within patients and the scientific community. Not only does our selectivity apply to other protein growth factors outside …See details»
Scholar Rock Provides Corporate Update and Highlights ... - Nasdaq
Jan 4, 2024 Investors & Media Rushmie Nofsinger Scholar Rock [email protected] [email protected] 857-259-5573 Source: Scholar Rock, Inc. Analyze your stocks, your waySee details»
Scholar Rock Announces Closing of Public Offering and Full …
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 16, 2023-- Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the …See details»
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of ...
CAMBRIDGE, Mass., May 22, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular …See details»
Our Science - Fighting Disease Using Technology - Scholar Rock
Jul 22, 2024 Structural Insights & the Growth Factor Precursor. Unlike traditional approaches, we target growth factors in their inactive precursor, or latent, forms to selectively regulate their …See details»
Scholar Rock Announces Proposed Public Offering of Common …
CAMBRIDGE, Mass., October 07, 2024--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal …See details»
Scholar Rock Announces New Preclinical Data for SRK-439 …
Nov 4, 2024 - Preclinical data show that SRK-439 increased lean mass and lowered fat mass gain in mice receiving metformin - Data support that Scholar Rock’s unique approach to …See details»
Scholar Rock Reports Full Year 2021 Financial Results and …
Dec 31, 2021 SRK-181 is a selective inhibitor of latent TGFβ1 activation being developed with the aim of overcoming primary resistance to and increasing the number of patients who may …See details»